Prognostic significance of CDC20 expression in malignancy patients: a meta-analysis

Abstract Background: A plenty of previous researches have reported the prognostic value of Cell Division Cycle Protein 20(CDC20) in malignancy tumors. Nevertheless, these researches were restricted by the small sample databases and the results were not strongly consistent among them.Methods: Databases involving EMBASE, PubMed, Cochrane Library and Web of Science were carefully searched, and literatures investigating the prognostic effect of aberrantly expressing CDC20 among human cancers were collected for further analysis. We used both hazards ratios and its corresponding 95% confidence intervals to evaluate the connection among the survival rate of malignancy patients and the expression of CDC20.Results: There were 10 eligible researches involving 2342 participants which were included in this study. The outcomes suggested that highly expressing CDC20 was significantly correlated with worse clinical prognosis of overall survival (OS) (HR 2.52, 95% CI 2.13-2.99) in the multivariate analysis, that (HR 2.05, 95% CI 1.50-2.82) in the univariate analysis and recurrence-free survival (HR 2.08, 95% CI 1.46-2.98). Moreover, we discovered that elevated CDC20 expression was significantly connected with decreased overall survival in non-small cell lung cancer (HR 2.40, 95% CI 1.91-3.02) while no significant relevance between highly expressing CDC20.Conclusions: this meta-analysis demonstrated that highly expressing CDC20 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.